Germany-based biotech InflaRx NV, has published positive Phase 2a data for a new small molecule drug for the treatment of two skin diseases: hidradenitis suppurativa and chronic spontaneous urticaria. The drug, INF904, is an inhibitor of the C5a receptor which modulates the body’s inflammatory responses. In a basket study of patients with the two diseases, the drug achieved rapid disease control. In the case of hidradenitis suppurativa this involved decreases in measures of nervous system changes.
